Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NTRA exchanges : Nasdaq save search
Liberty All-Star® Growth Fund, Inc. March 2024 Monthly Update
Published: 2024-04-12 (Crawled : 00:20) - prnewswire.com
AMZN 4 | $184.03 0.22% 6.9M
|
Retail Trade
| Email alert
Add to watchlist
TRNS | $109.83 -0.42% 4.4K
|
Electronic Technology
| Email alert
Add to watchlist
PGNY | $33.5 -0.92% 12K
|
Commercial Services
| Email alert
Add to watchlist
VERX S | $30.055 -4.1% 13K
|
Technology Services
| Email alert
Add to watchlist
SPSC | $164.34 -3.13% 4.9K
|
Technology Services
| Email alert
Add to watchlist
NTRA | $90.445 0.03% 210K
|
Health Services
| Email alert
Add to watchlist
CWST | $94.84 -0.84% 37K
|
Industrial Services
| Email alert
Add to watchlist
EME | $346.38 -0.26% 41K
|
Industrial Services
| Email alert
Add to watchlist
SITE | $164.37 -1.23% 5.5K
|
Distribution Services
| Email alert
Add to watchlist
CR | $130.295 -0.68% 13K
|
Producer Manufacturing
| Email alert
Add to watchlist
star update liberty growth
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Published: 2024-04-11 (Crawled : 00:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.36%
H: 0.0%
C: 0.0%
kidney publication study
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 0.92%
H: 0.26%
C: -2.26%
test for heart
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.6%
H: 2.8%
C: 2.25%
cancer trials trial
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 0.19%
H: 1.46%
C: 0.48%
cancer trial
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 0.07%
H: 1.68%
C: 1.65%
breast meeting
Natera to Participate in March Investor Conferences
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 11.99%
H: 5.68%
C: 0.89%
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
Published: 2024-02-20 (Crawled : 14:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -1.86%
H: 2.81%
C: 2.47%
conference
Liberty All-Star® Growth Fund, Inc. January 2024 Monthly Update
Published: 2024-02-13 (Crawled : 23:00) - prnewswire.com
SITE | $164.37 -1.23% 5.5K
|
Distribution Services
|
| O: 5.13%
H: 4.44%
C: 3.2%
DT 4 | $44.305 -1.41% 280K
|
Technology Services
|
| O: 0.85%
H: 1.33%
C: 0.5%
CR | $130.295 -0.68% 13K
|
Producer Manufacturing
|
| O: 1.1%
H: 1.6%
C: 0.56%
WDAY F | $257.885 -0.67% 150K
|
Technology Services
|
| O: 0.9%
H: 1.46%
C: 0.95%
VERX S | $30.055 -4.1% 13K
|
Technology Services
|
| O: 0.12%
H: 3.29%
C: 3.17%
TRNS | $109.83 -0.42% 4.4K
|
Electronic Technology
|
| O: 0.84%
H: 0.97%
C: -0.25%
SPSC | $164.34 -3.13% 4.9K
|
Technology Services
|
| O: 1.59%
H: 0.96%
C: -0.02%
RPD | $44.34 -3.08% 55K
|
Technology Services
|
| O: 1.87%
H: 1.69%
C: 1.25%
PGNY | $33.5 -0.92% 12K
|
Commercial Services
|
| O: 1.62%
H: 0.38%
C: -0.34%
PLMR | $74.94 -0.36% 4.6K
|
Finance
|
| O: 0.03%
H: 6.33%
C: 4.63%
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 1.08%
H: 1.37%
C: 0.77%
CWST | $94.84 -0.84% 37K
|
Industrial Services
|
| O: 0.99%
H: 3.81%
C: 3.77%
AMZN 4 | $184.03 0.22% 6.9M
|
Retail Trade
|
| O: 0.34%
H: 1.18%
C: 1.05%
AGYS 4 | $81.33 -1.78% 10K
|
Technology Services
|
| O: 1.27%
H: 1.74%
C: 0.75%
star update liberty growth
New Study Validates Signatera™ in Endometrial Cancer
Published: 2024-02-05 (Crawled : 13:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.89%
H: 2.74%
C: 2.52%
cancer study
Carrier Screening Market Worth $5.4 Billion | MarketsandMarkets™
Published: 2024-01-31 (Crawled : 15:30) - prnewswire.com
TMO | $554.06 -0.68% 110K
|
Health Technology
|
| O: -0.67%
H: 0.48%
C: -4.32%
DGX | $129.28 0.5% 42K
|
Health Services
|
| O: 0.46%
H: 0.41%
C: -0.76%
LH | $204.0 0.33% 59K
|
Health Services
|
| O: 0.53%
H: 0.0%
C: -2.31%
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: -0.2%
H: 2.4%
C: -3.7%
OPK | $1.23 280K
|
Health Technology
|
| O: 0.0%
H: 4.95%
C: 0.99%
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.76%
H: 2.2%
C: 0.67%
ILMN | $118.87 -1.89% 420K
|
Health Technology
|
| O: -0.49%
H: 1.17%
C: -2.37%
CNTG | $0.49 19K
|
Commercial Services
|
| O: -0.86%
H: 0.0%
C: -0.43%
market
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -1.07%
H: 1.73%
C: 0.46%
lung cancer publication risk
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Published: 2024-01-25 (Crawled : 13:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 0.59%
H: 0.64%
C: -2.09%
gastrointestinal
Invitae Completes Sale of Reproductive Health Assets to Natera
Published: 2024-01-22 (Crawled : 15:30) - biospace.com/
NVTA | $0.019 0.0% 22M
|
Health Services
|
| O: -2.76%
H: 0.0%
C: 0.0%
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 2.3%
H: 1.12%
C: -2.17%
health
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
Published: 2024-01-09 (Crawled : 14:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.31%
H: 5.34%
C: 2.24%
year
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
Published: 2023-12-21 (Crawled : 15:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 1.62%
H: 5.36%
C: 3.57%
unique study benefits
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 1.08%
H: 0.45%
C: -1.71%
breast cancer treatment sabcs
Natera Announces Real-World Data Collaboration with Merck
Published: 2023-11-14 (Crawled : 14:30) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: 2.95%
H: 4.4%
C: 4.3%
merck collaboration
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
NTRA | $90.445 0.03% 210K
|
Health Services
|
| O: -0.09%
H: 0.0%
C: -5.18%
breast cancer treat trial
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $7.41 78.13% 14M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 25M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.